John Bridgeman
Co-Founder & Chief Scientific Officer Immunokey
Dr. John Bridgeman is a highly accomplished immunotherapy expert with a 20 year history converting scientific ideas into tangible therapies. With a PhD from the University of Manchester and further training at Cardiff University, John has a deep understanding of chimeric antigen receptor (CAR) biology. Over his career, John established and led the R&D team, developing novel gene engineering strategies, managing IP portfolios, and driving projects from concept to clinical execution. He has made significant strides in advancing cell-based therapies, with a proven track record in patent filings, generating novel concepts, and progressing them through to phase 1 clinical trials.
Seminars
Tuesday 9th February 2027
Advancing Novel CAR Therapies Through a Comprehensive Discovery Engine
2:15 pm
- Identifying novel solid tumour targets through bioinformaticsdriven discovery to establish a strong foundation for CAR development
- Screening receptors and performing functional assays with patient-derived samples and in vitro models to select the optimal candidate for in vivo evaluation
- Evaluating data to select a candidate for preclinical development
